Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Celgene
Sellas Life Sciences Group
Kura Oncology, Inc.
Faron Pharmaceuticals Ltd
CellCentric Ltd.
Incyte Corporation
Treadwell Therapeutics, Inc
Pfizer
Gilead Sciences
Prelude Therapeutics
Celgene
Celgene
S*BIO